2000
DOI: 10.1006/cimm.2000.1693
|View full text |Cite
|
Sign up to set email alerts
|

Mechanism of Cytotoxicity Induced by Chimeric Mouse Human Monoclonal Antibody IDEC-C2B8 in CD20-Expressing Lymphoma Cell Lines

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
92
0
8

Year Published

2003
2003
2017
2017

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 136 publications
(101 citation statements)
references
References 36 publications
1
92
0
8
Order By: Relevance
“…Flieger et al [32] have shown that rituximab alone induced apoptosis in Raji lymphoma cell lines at a concentration above 100 ng/ml. There is general agreement that hyper-cross-linking enhances the apoptotic effects of CD20 mAbs [33].…”
Section: Ao/eb Double Fluorescent Stainingmentioning
confidence: 99%
“…Flieger et al [32] have shown that rituximab alone induced apoptosis in Raji lymphoma cell lines at a concentration above 100 ng/ml. There is general agreement that hyper-cross-linking enhances the apoptotic effects of CD20 mAbs [33].…”
Section: Ao/eb Double Fluorescent Stainingmentioning
confidence: 99%
“…NHL histological subtypes at enrollment included 7 follicular lymphoma (4 grade I and 3 grade II), 4 diffuse large cell lymphoma, 2 small cell lymphocytic lymphoma, 1 extranodal marginal zone lymphoma, and 1 mantle cell lymphoma ( Table 1). The median number of prior therapies was 4 (range, [2][3][4][5][6][7][8][9][10][11][12][13][14]. Ten patients who participated in study NHL02 had been treated previously with a total of 16 prior courses of rituximab therapy, alone (n ϭ 13), with combination chemotherapy (n ϭ 2), or with chemotherapy and transplantation (n ϭ 1).…”
Section: Patient Characteristicsmentioning
confidence: 99%
“…Although rituximab has multiple mechanisms of action, antibody-dependent cell-mediated cytotoxicity (ADCC) is of particular importance. Neutralizing antibodies that prevent the Fc-FcR-g interaction abrogate the B-celldepleting and antilymphoma activity in vitro 13 and in vivo in murine models. [14][15][16] In clinical practice, FcgRIIIA polymorphism with a higher affinity for IgG1 is associated with a higher response rate.…”
Section: Introductionmentioning
confidence: 99%